Jochen Kruip

USPTO Granted Patents = 19 (Patent Applications = 19)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 21)

Average Co-Inventor Count = 8.6

ph-index = 5

Forward Citations = 90(Granted Patents)

Location History:

Frankfurt-am-Main, DE (2018 - 2021)
Erzhausen, DE (2013 - 2023)

Company Filing History:

Pieris Pharmaceuticals Gmbh

patents

1 out of 5,309

Leland Stanford Junior University

patents

where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11779651 - Bivalent, bispecific binding proteins for prevention or treatment of HIV infection (2023-10-10),

2. 11453727 - Antibodies that bind IL-4 and/or IL-13 and their uses (2022-09-27),

3. 11129905 - Bivalent, bispecific binding proteins for prevention or treatment of HIV infection (2021-09-28),

4. 10947284 - Fusion molecules (2021-03-16),

5. 10759871 - Antibodies that bind IL-4 and/or IL-13 and their uses (2020-09-01),

6. 10329334 - Proteins specific for pyoverdine and pyochelin (2019-06-25),

7. 10316071 - Fusion molecules (2019-06-11),

8. 10118952 - Proteins specific for pyoverdine and pyochelin (2018-11-06),

9. 10072056 - Proteins specific for pyoverdine and pyochelin (2018-09-11),

10. 10065998 - Proteins specific for pyoverdine and pyochelin (2018-09-04),

11. 9989524 - Immuno imaging agent for use with antibody-drug conjugate therapy (2018-06-05),

12. 9884898 - Proteins specific for pyoverdine and pyochelin (2018-02-06),

13. 9844607 - Immuno imaging agent for use with antibody-drug conjugate therapy (2017-12-19),

14. 9738728 - Antibodies that bind IL-4 and/or IL-13 and their uses (2017-08-22),

15. 9732162 - Antibodies that bind IL-4 and/or IL-13 and their uses (2017-08-15),

Title: **Jochen Kruip: Innovator in Biopharmaceuticals**

Introduction

Jochen Kruip, based in Erzhausen, Germany, is a notable inventor with a remarkable portfolio of 19 patents. His innovative contributions primarily focus on the development of biopharmaceuticals for the prevention and treatment of diseases, particularly related to HIV and allergic conditions.

Latest Patents

Kruip's recent patents include groundbreaking advancements in medical technology. One such invention is the "Bivalent, bispecific binding proteins for prevention or treatment of HIV infection," which features proteins that can specifically bind to two different HIV-1 Env protein epitopes. Another significant patent involves "Antibodies that bind IL-4 and/or IL-13 and their uses," which pertains to humanized anti-IL-4 and IL-13 antibodies designed to treat or mitigate diseases like allergic asthma and dermatitis.

Career Highlights

Throughout his career, Kruip has made substantial contributions to the pharmaceutical industry, particularly during his time at renowned companies like Sanofi and Pieris Pharmaceuticals GmbH. His work in these institutions has contributed to the advancement of therapeutic strategies and innovative treatments.

Collaborations

Jochen Kruip has collaborated with talented professionals in the field, including Ercole Rao and Carsten Corvey. These collaborations have fostered a rich environment for innovation, combining diverse expertise to tackle complex medical challenges.

Conclusion

With an impressive array of patents and pivotal roles in leading pharmaceutical companies, Jochen Kruip continues to be a driving force in the field of biopharmaceutical innovation. His dedication to developing therapies for HIV and allergic disorders showcases his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.